The recurrent conjoined gene ESR1-CCDC170 occurring in nearly 4% of ER-positive clinical breast cancer patients has been proven to be a causative fusion oncogene underlying breast carcinogenesis [17]. The gene discussed is ESR1; the disease is breast cancer.